Arcutis Biotherapeutics (ARQT) Corporate presentation summary

Strategic growth initiatives

• Focus on expanding ZORYVE through conversion from topical steroids, primary care/pediatric expansion, and new indications, supported by ongoing data generation.

• Pipeline development includes ARQ-234 for atopic dermatitis and exploration of external innovation sources.

Commercial and financial performance

• Achieved $372.1 million in net product revenue for 2025, a 123% year-over-year increase, with ZORYVE holding ~45% share of the branded non-steroidal topical segment.

• Q4 2025 product revenues reached $127.5 million, with net income of $17.4 million, marking a turnaround from prior losses.

• Ended 2025 with $221 million in cash and equivalents and $108 million in net debt, maintaining cash flow breakeven.

Market opportunity and expansion

• Dermatology market opportunity includes 30M diagnosed patients, with 19M topically treated and 8M currently targeted by dermatology specialists.

• Growth strategy aims to expand the serviceable obtainable market to 17M by targeting primary care and pediatric providers.

• ZORYVE’s prescription share and volume have grown rapidly, reaching 22,000 weekly TRx by end of 2025.